高剂量高频阿柏西普治疗难治性新生血管性年龄相关性黄斑变性
这项回顾性干预病例系列研究纳入对每月雷珠单抗或贝伐单抗耐药的新生血管性年龄相关性黄斑变性患眼,逐步升级至每4周4 mg阿柏西普(4Q4W)治疗;33眼平均随访16个月,启动4Q4W后平均3.8个月实现视网膜干燥,黄斑厚度及积液显著下降并维持至末次随访,45%患眼视力提高≥1行,9%患眼新发地图状萎缩,未发生眼部或全身不良事件。
要点
- 对每月雷珠单抗/贝伐单抗耐药的新生血管性年龄相关性黄斑变性,逐步升级至每4周4 mg阿柏西普可使视网膜干燥。
- 启动4Q4W阿柏西普后平均3.8个月实现无视网膜内或视网膜下液,形态学疗效维持至末次随访。
- 45%患眼视力提高≥1行,9%患眼随访期间新发地图状萎缩,未发生眼部或全身不良事件。
核心结论
- 玻璃体腔内注射高剂量高频阿柏西普是难治性湿性年龄相关性黄斑变性的有效治疗。
研究设计与样本
- 回顾性干预病例系列,对湿性年龄相关性黄斑变性患者采用逐步剂量升级治疗。
- 对每月(Q4W)雷珠单抗/贝伐单抗耐药的非玻璃体切除患眼,换用每8周2 mg阿柏西普;若仍耐药,升级至每4周2 mg阿柏西普,再升级至每4周4 mg(高剂量高频,4Q4W)阿柏西普。
- 耐药定义为≥3次注射后干燥但出现≥2次复发,或≥5次注射治疗下持续渗出。
- 共33眼(28例患者)接受4Q4W阿柏西普治疗,平均随访16个月。
主要发现
- 启动4Q4W阿柏西普治疗后平均3.8个月实现视网膜干燥(无视网膜内或视网膜下液)。
- 启动4Q4W阿柏西普后1个月,中心凹厚度、最大中心凹厚度、视网膜内液、视网膜下液及视网膜色素上皮脱离高度显著下降,形态学疗效维持至末次随访。
- 45%患眼视力提高≥1行。
- 随访期间9%患眼新发地图状萎缩。
- 启动4Q4W阿柏西普后未发生眼部或全身不良事件。
关键数值与推荐
- 4Q4W阿柏西普剂量为每4周4 mg(0.1 mL)。
- 耐药定义为≥3次注射后干燥但出现≥2次复发,或≥5次注射治疗下持续渗出。
临床怎么用
- 原文结论认为玻璃体腔内高剂量高频阿柏西普是难治性湿性年龄相关性黄斑变性的有效治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration). METHODS: This was a retrospective interventional case series in which patients with wet age-related macular degeneration were treated with stepwise dose escalation. Nonvitrectomized patients resistant to monthly (Q4W) ranibizumab/bevacizumab were switched to 2 mg aflibercept every 8 weeks. With resistance, they were escalated to Q4W 2 mg aflibercept, then Q4W 4 mg (high dose high frequency, 4Q4W) aflibercept. Resistance was defined as ≥2 recurrences after being dry following ≥3 injections or persistent exudation on treatment of ≥5 injections. RESULTS: Thirty-three eyes of 28 patients were treated with 4Q4W aflibercept and followed for a mean of 16 months. A dry retina (no intraretinal or subretinal fluid) was achieved after initiating 4Q4W aflibercept treatment at a mean of 3.8 months. Central foveal thickness, maximum foveal thickness, intraretinal fluid, subretinal fluid, and retinal pigment detachment height decreased significantly at 1 month after initiating the 4Q4W aflibercept, and the morphologic therapeutic effect was sustained until the last visit. Forty-five percent of eyes had one or more lines of vision improvement. New geographic atrophy developed in 9% of eyes during follow-up. No ocular or systemic adverse events occurred after initiating 4Q4W aflibercept. CONCLUSION: Intravitreal high-dose high-frequency aflibercept is an effective treatment for patients with refractory wet age-related macular degeneration.
引用
- You QS, Gaber R, Meshi A, et al. HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2018. PMID: 28604541. doi:10.1097/IAE.0000000000001726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。